Modified Citrus Pectin

Low-MW pectin: Gal-3 ↓, adhesion/metastasis ↓, immune ↕; moderate signals in prostate/ovarian/colorectal/breast.

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Promising Gal-3 blockade with small human studies; larger RCTs ongoing.MCPPectaSol

Forms: Powder (5-15 g scoops) · Capsules (standardized low-MW, 5 g/serving)

Educational only, not medical advice. OncoForge makes no claim that Modified Citrus Pectin treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Soluble, low–molecular-weight pectin binds galectin-3, disrupting tumor cell adhesion, aggregation, and microenvironmental signaling; small human studies (notably in prostate cancer) show biomarker improvements and disease-stabilization signals.

Evidence at a glance

Tier 2 · animalProstateOvarianColorectalBreast

Preclinical gal-3/CTC dominance; phase II prostate (NCT01681823) PSA signals; ongoing trials in solid tumors; meta limited by heterogeneity.

How it may work

MCP blocks galectin-3 carbohydrate recognition domains, preventing lattice formation that supports cell–cell/ECM adhesion, angiogenesis, and immune evasion. This can reduce circulating tumor cell aggregation, tumor emboli, and metastatic colonization. Additional effects include macrophage polarization shifts and microbiome interactions.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Galectin-3↓CRD binding to disrupt lattice formation
Adhesion↓Cell-cell/ECM interactions reduced
Metastasis↓CTC aggregation and colonization ↓
Immune↕Macrophage M1 shift and T-cell support
Angiogenesis↓Via galectin-3 blockade

Galectin-3AdhesionMetastasisImmune

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Docetaxel: Delayed PSA rise and better TTP in prostate phase II.
Cisplatin: Reduced metastatic burden in ovarian preclinical.
Curcumin: Additive gal-3/adhesion inhibition in colorectal models.
Resveratrol: Cooperative anti-metastatic in breast cancer.

Overlapping mechanisms

Galectin-3: Overlaps with TD139-like inhibitors; monitor biomarkers.
Immune ↕: Modest effects may not stack with strong immunomodulators.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Gi UpsetDrug BindingAllergy Risk

Potential interactions

oral_medicationsSeparateLowTheoreticalPectin binding may reduce absorption.
chemotherapySynergizeLowTheoreticalEnhances anti-metastatic effects.
DocetaxelSynergizeLowTheoreticalStabilizes PSA in prostate adjunct.

Timing

Between-meals: Optimizes gut transit and binding.
TID: Divided for steady galectin-3 neutralization.

References

Research

No published studies for Modified Citrus Pectin yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Modified Citrus Pectin depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 5–15 g/day (po) divided doses; mixed in water/juice, Adjunct 5-10 g/day divided; up to 15 g for aggressive protocols; low-MW for absorption; cycle 3 weeks on/1 off if needed..

Trials studying Modified Citrus Pectin

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar